跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML2196

Sigma-Aldrich

Zotarolimus

≥95% (HPLC)

别名:

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin, ABT-578

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C52H79N5O12
CAS号:
221877-54-9
分子量:
966.21
MDL编号:
MFCD09752954
UNSPSC代码:
51111800
NACRES:
NA.77

方案

≥95% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

C[C@H](CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@H](OC)[C@@H](/C(C)=C/[C@@H](C)C1=O)O)=O)C)C)O2)[C@]2(O)C(C(N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]4CC[C@H](N5N=NN=C5)[C@H](OC)C4)C1)=O)=O)=O

InChI

1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

InChI key

CGTADGCBEXYWNE-JUKNQOCSSA-N

生化/生理作用

Rapamycin analog with immunosuppressant and anti-proliferative activity used in coronary stents
Zotarolimus (ABT-578) is a semi-synthetic rapamycin analog with immunosuppressant and anti-proliferative activity. It binds to the FKBP12 binding protein, which subsequently binds to the mammalian target of rapamycin (mTOR) causing cell cycle arrest in the G1 phase. Zotarolimus was designed to be used for delivery from drug-eluting coronary stents to prevent restenosis.
Zotarolimus is a second generation Drug Eluting Stent (DES).

储存分类代码

11 - Combustible Solids

WGK

WGK 3

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates
Valgimigli M, et al.
Journal of the American College of Cardiology, 65(8), 805-815 (2015)
Yuji Nishimoto et al.
Journal of cardiology, 70(3), 297-302 (2016-12-31)
First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than
Keiichiro Miura et al.
Cardiovascular revascularization medicine : including molecular interventions, 16(6), 344-347 (2015-08-09)
Late and very late stent thrombosis after drug-eluting stent implantation is a major concern. The present study evaluated difference in the effects of sirolimus, paclitaxel and zotarolimus on endothelial cells. Mouse endothelial cells were seeded in a 6-well plate. Cells
Fabrizio D'Ascenzo et al.
European heart journal, 38(42), 3160-3172 (2017-10-12)
The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Randomized controlled trials

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持